Dna Biomed Solns Stock Working Capital
| DNA Stock | ILS 88.60 1.60 1.84% |
DNA Biomed Solns fundamentals help investors to digest information that contributes to DNA Biomed's financial success or failures. It also enables traders to predict the movement of DNA Stock. The fundamental analysis module provides a way to measure DNA Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNA Biomed stock.
DNA |
DNA Biomed Solns Company Working Capital Analysis
DNA Biomed's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current DNA Biomed Working Capital | 18 M |
Most of DNA Biomed's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNA Biomed Solns is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
According to the company's disclosures, DNA Biomed Solns has a Working Capital of 18 M. This is 95.77% lower than that of the Electronic Equipment, Instruments & Components sector and 96.66% lower than that of the Information Technology industry. The working capital for all Israel stocks is 98.78% higher than that of the company.
DNA Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNA Biomed's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNA Biomed could also be used in its relative valuation, which is a method of valuing DNA Biomed by comparing valuation metrics of similar companies.DNA Biomed is currently under evaluation in working capital category among its peers.
DNA Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Shares Owned By Insiders | 54.87 % | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Net Income | 18.37 M | |||
| Cash And Equivalents | 492 K | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (2.33 M) | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 11 | |||
| Beta | 0.31 | |||
| Market Capitalization | 86.46 M | |||
| Total Asset | 54.62 M | |||
| Retained Earnings | (139 M) | |||
| Working Capital | 18 M | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
| Z Score | -2.8 | |||
| Net Asset | 54.62 M |
About DNA Biomed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNA Biomed Solns's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNA Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNA Biomed Solns based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DNA Stock
DNA Biomed financial ratios help investors to determine whether DNA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DNA with respect to the benefits of owning DNA Biomed security.